Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.
Protein kinase C related kinase 1 (PRK1) is a component of Rho-GTPase, androgen receptor, histone demethylase and histone deacetylase signaling pathways implicated in prostate and ovarian cancer. Herein we describe the crystal structure of PRK1 in apo form, and also in complex with a panel of litera...
Main Authors: | Philip Chamberlain, Silvia Delker, Barbra Pagarigan, Afshin Mahmoudi, Pilgrim Jackson, Mahan Abbasian, Jeff Muir, Neil Raheja, Brian Cathers |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4128815?pdf=render |
Similar Items
-
Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.
by: Nicole Pinto, et al.
Published: (2018-01-01) -
Lestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cells.
by: Jens Köhler, et al.
Published: (2012-01-01) -
Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis.
by: Tania Diaz, et al.
Published: (2011-01-01) -
Lestaurtinib (CEP-701) Potentiates the Anticonvulsant Effect of Phenobarbital against Kainic Acid-induced Status Epilepticus
by: Kuk, Raafat
Published: (2018) -
LASIK, SMILE and PRK:advantages and indications
by: Farideh Doroodgar, et al.
Published: (2019-10-01)